Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326101971> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2326101971 endingPage "672" @default.
- W2326101971 startingPage "672.13" @default.
- W2326101971 abstract "<h3>Objectives</h3> To compare safety data in patients (pts) with early (<2 years duration) RA who were randomly assigned to receive 4 different regimens of DMARDs treatment. <h3>Methods</h3> One hundred forty-one pts with RA of less than 2 years duration (122 women, mean age 51 years, mean disease duration 24 weeks, mean DAS 28 5,9; 64% RF-positive,59% ACCP-positive) were randomly allocated to receive one of the following treatment regimens: methotrexate (MTX, up to 20 mg/week, 35 pts); MTX plus prednisolone (P) 10 mg daily (MTX-P, 34 pts); MTX-P plus methylprednisolone (MP) 1000 mg intravenously on the first day of treatment (MTX-P-MP, 35 pts); leflunomide 20 mg daily (LEF, 37 pts). Duration of treatment was one year. Control points were 3, 6 and 12 months from the initiation of therapy. Safety data was assessed at the main control points. <h3>Results</h3> At baseline all groups were comparable in their demographic, clinical and radiographic characteristics. One hundred twenty-seven pts completed the study. Side effects were registered in the same number of patients in each group (9 patients; 24,3%>26%). Therapy had to be stopped in six patients due to side effects: MTX - 1(depigmentation of the skin), MTX-P - none, MTX-P-MP - 1 (stomatitis) and LEF - 4 (dermatitis-2; pancytopenia with platelet count 43 ×10<sup>9</sup>/L, erythrocyte 2,9×10<sup>12</sup>/L, WBC 2×10<sup>9</sup>/L-1; angioedema, periorbital edema and dermatitis with itching-1). Other side effects were mild: MTX - 8 pts (dyspepsia-1, elevation of transaminases-6, hair loss-1), MTX-P - 9 pts (Cushing’s syndrome - 1, hair loss - 1, anemia - 1, elevation of transaminases - 4, arterial hypertension - 2), MTX-P-MP - 8 pts (hair loss-1,dermatitis-1, elevation of transaminases-5, Cushing’s syndrome - 1) and LEF - 5 pts (elevation of transaminases-5). <h3>Conclusions</h3> Safety profile was the same in all groups. In most cases side effects were moderate or minimal. The most serious side effects, leading to the discontinuation of the therapy, were registered in LEF group. There was no withdrawal of treatment in MTX-P group. <h3>Disclosure of Interest</h3> None Declared" @default.
- W2326101971 created "2016-06-24" @default.
- W2326101971 creator A5028439800 @default.
- W2326101971 creator A5047607550 @default.
- W2326101971 creator A5049547284 @default.
- W2326101971 creator A5077717580 @default.
- W2326101971 creator A5084805243 @default.
- W2326101971 creator A5087535771 @default.
- W2326101971 date "2013-06-01" @default.
- W2326101971 modified "2023-09-25" @default.
- W2326101971 title "AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients" @default.
- W2326101971 doi "https://doi.org/10.1136/annrheumdis-2012-eular.597" @default.
- W2326101971 hasPublicationYear "2013" @default.
- W2326101971 type Work @default.
- W2326101971 sameAs 2326101971 @default.
- W2326101971 citedByCount "1" @default.
- W2326101971 countsByYear W23261019712016 @default.
- W2326101971 crossrefType "journal-article" @default.
- W2326101971 hasAuthorship W2326101971A5028439800 @default.
- W2326101971 hasAuthorship W2326101971A5047607550 @default.
- W2326101971 hasAuthorship W2326101971A5049547284 @default.
- W2326101971 hasAuthorship W2326101971A5077717580 @default.
- W2326101971 hasAuthorship W2326101971A5084805243 @default.
- W2326101971 hasAuthorship W2326101971A5087535771 @default.
- W2326101971 hasConcept C126322002 @default.
- W2326101971 hasConcept C141071460 @default.
- W2326101971 hasConcept C197934379 @default.
- W2326101971 hasConcept C2775905006 @default.
- W2326101971 hasConcept C2776715498 @default.
- W2326101971 hasConcept C2777575956 @default.
- W2326101971 hasConcept C2779382419 @default.
- W2326101971 hasConcept C2780007613 @default.
- W2326101971 hasConcept C2781059491 @default.
- W2326101971 hasConcept C71924100 @default.
- W2326101971 hasConcept C90924648 @default.
- W2326101971 hasConceptScore W2326101971C126322002 @default.
- W2326101971 hasConceptScore W2326101971C141071460 @default.
- W2326101971 hasConceptScore W2326101971C197934379 @default.
- W2326101971 hasConceptScore W2326101971C2775905006 @default.
- W2326101971 hasConceptScore W2326101971C2776715498 @default.
- W2326101971 hasConceptScore W2326101971C2777575956 @default.
- W2326101971 hasConceptScore W2326101971C2779382419 @default.
- W2326101971 hasConceptScore W2326101971C2780007613 @default.
- W2326101971 hasConceptScore W2326101971C2781059491 @default.
- W2326101971 hasConceptScore W2326101971C71924100 @default.
- W2326101971 hasConceptScore W2326101971C90924648 @default.
- W2326101971 hasIssue "Suppl 3" @default.
- W2326101971 hasLocation W23261019711 @default.
- W2326101971 hasOpenAccess W2326101971 @default.
- W2326101971 hasPrimaryLocation W23261019711 @default.
- W2326101971 hasRelatedWork W2092881439 @default.
- W2326101971 hasRelatedWork W2352294526 @default.
- W2326101971 hasRelatedWork W2372955595 @default.
- W2326101971 hasRelatedWork W2388245966 @default.
- W2326101971 hasRelatedWork W2390018151 @default.
- W2326101971 hasRelatedWork W2394123269 @default.
- W2326101971 hasRelatedWork W3030711132 @default.
- W2326101971 hasRelatedWork W3032539365 @default.
- W2326101971 hasRelatedWork W3112668959 @default.
- W2326101971 hasRelatedWork W4226067500 @default.
- W2326101971 hasVolume "71" @default.
- W2326101971 isParatext "false" @default.
- W2326101971 isRetracted "false" @default.
- W2326101971 magId "2326101971" @default.
- W2326101971 workType "article" @default.